drugset / Trial / NCT00101738

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738

Phase 3 Completed 342 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

Timeline

Start
2003-03
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject mycophenolic acid Small molecule

Indications

No indication recorded.